

## *Regulation of Lipid Synthesis*

This unit will cover the synthesis of lipids including cholesterol, fatty acid and triglyceride synthesis. For more details on these topics, refer to Chapters 28 and 29 in *Biochemistry: A Short Course* available in reserve<sup>1</sup>.

<sup>1</sup> John L Tymoczko, Jeremy M Berg, and Lubert Stryer. *Biochemistry: A Short Course*. W.H. Freeman and Co, New York, NY, 3rd edition, 2015

### *Contents*

<i>Learning Objectives</i>	2
<i>Synthesis of Triglycerides from Fatty Acids</i>	2
<i>Glycerol-3-Phosphate Supply for Triglycerides</i>	4
<i>Regulation of Triglyceride Esterification Enzymes</i>	5
<i>De Novo Fatty Acid Synthesis</i>	5
<i>Fatty Acid Synthesis from Glucose and Ketogenic Amino Acids</i>	5
<i>Desaturation of Fatty Acids</i>	7
<i>Regulation of Fatty Acid Synthesis</i>	7
<i>Lipodistrophy Results from Impaired Triglyceride Storage</i>	8
<i>Cholesterol Synthesis</i>	9
<i>The Relationship Between Dietary Fat and Cholesterol Synthesis</i>	11

### Learning Objectives

- Describe the conditions and tissues wherein fatty acids are generated, and from what precursors.
- Explain the regulation of fatty acid biosynthesis by metabolite levels and hormones, including how it is ensured that  $\beta$ -oxidation and *de novo* lipogenesis do not occur simultaneously.
- Understand the energy costs of generating fatty acids from glucose, compared with using glucose for fuel. Included in this is the source of carbon units, and reducing equivalents that are necessary for fatty acid biogenesis.
- Analyse the role of citrate in co-ordination of glycolysis, TCA cycle activity and lipogenesis.
- Explain the causes of lipodystrophy, including the metabolic consequences of ectopic fat deposition.
- Understand how transcriptional and post-translational regulation control triglyceride synthesis and cholesterol synthesis.
- Analyse the cellular conditions that lead to cholesterol synthesis and ketogenesis.
- Describe the roles and activation of SREBP1 and SREBP2 in fatty acid/triglyceride and cholesterol biogenesis respectively.

### Synthesis of Triglycerides from Fatty Acids

Fatty acids are obtained from the diet, or can be made from excess glucose/amino acids<sup>2</sup>. The esterification of these fatty acids within cells is very important because free fatty acids can be toxic to a cell once they build up. Most tissues are able to store excess fatty acids to some degree but the major sites of synthesis are adipose tissue, and liver.

Generally cells have to decide between three general fates for the fatty acids that arrive inside the cell<sup>3</sup>:

*Without energy demand:* esterify with glycerol as triglycerides

*With energy demand, but with OAA availability:* oxidize fatty acid to Acetyl-CoA and use that for fuel in the TCA cycle to generate ATP.

*With energy demand but insufficient OAA:* oxidize to Acetyl-CoA and convert that to ketone bodies for release (primarily in the liver<sup>4</sup>).

<sup>2</sup> A process known as *de novo* lipogenesis.

<sup>3</sup> Though in growing and dividing cells, the fraction of fatty acids that become phospholipids becomes much more relevant.

<sup>4</sup> Two main reasons why this is mainly in the liver, the first is that there is typically less cataplerosis in non-hepatic tissues because there is less gluconeogenesis. The second is that the enzymes of ketogenesis are at higher levels in the liver.


We will discuss the regulation of  $\beta$ -oxidation, which is the main process by which fatty acids become Acetyl-CoA in the next lecture. When fatty acid synthesis is active, the elevations in malonyl-CoA<sup>5</sup> will generally suppress  $\beta$ -oxidation via inhibition of Carnitine Palmitoyltransferase I<sup>6</sup>. This ensures that fatty acid synthesis and oxidation do not occur simultaneously.

<sup>5</sup> Described below





<sup>6</sup> Which is the rate limiting step of fatty acid breakdown.

TRIGLYCERIDE SYNTHESIS INVOLVES THE SEQUENTIAL ADDITION OF FATTY ACIDS TO A GLYCEROL BACKBONE. This involves enzymatic reactions starting with phosphorylated glycerol and an activated fatty acid. To prepare fatty acids for esterification, an fatty acid<sup>7</sup> is conjugated to coenzyme A by Acyl-CoA Synthetase:

<sup>7</sup> Also known as an acyl group



Note that this reaction *consumes* two high ATP equivalents for each fatty acid to be added. This fatty acid is now in the *activated* form and is available to be conjugated to phosphorylated glycerol by the following four sequential reactions:



THE PHOSPHATIDIC ACID GENERATED IN STEP 3 IS THE PRECURSOR FOR MOST PHOSPHOLIPIDS. Enzymes can convert phosphatidic acid to phosphatidylserine, or phosphatidylinositol. Phosphatidylserine is the substrate for the generation of phosphatidylethanolamine, which in turn generates phosphatidylcholine<sup>8</sup> For more details about phospholipid synthesis see Kent [1995]. These structural lipids are particularly important during development, and are targets to reduce the growth of cancer cells, which require generation of substantial membranes.

<sup>8</sup> This is the reaction catalyzed by *PEMT*, the enzyme that has variants which convert choline dependence.


FATTY ACIDS ARE ADDED IN A SPECIFIC MANNER. Generally at the sn2 position is an unsaturated fatty acid, while there are saturated fats at the sn1 position. The sn3 position seems to have much less specificity in mammalian triglyceride formation [Brockerhoff, 1971]. This is relevant for phospholipids that form membranes, as these will

tend to have one saturated and one unsaturated fatty acid at each of the sn1 and sn2 positions<sup>9</sup>.

<sup>9</sup> The sn3 position is where the phosphate group is located.


### *Glycerol-3-Phosphate Supply for Triglycerides*

While each triglyceride molecule needs three fatty acids, they also require a phosphorylated glycerol backbone for reaction 2. The source of this glycerol varies between tissues. In the liver, glycerol can be generated by phosphorylation of glycerol via Glycerol Kinase at a cost of an ATP:



Adipocytes on the other hand have low levels of glycerol kinase activity. Therefore when fatty acids are presented to adipocytes they *require* glycerol to be made from glucose. The glycolytic intermediate dihydroxyacetone phosphate (DHAP) is generated by Aldolase<sup>10</sup> and can be converted into glycerol.

<sup>10</sup> Two steps *after* PFK<sub>1</sub>



This reaction comes at a cost of one NADH molecule, or 2.5 ATP equivalents. The lack of glycerol kinase in adipocytes is thought to be an adaptation to prevent the futile release and then re-esterification of fatty acids, whereas after lipolysis in adipocytes *both* glycerol and fatty acids can go to the liver, so the liver always has sufficient glycerol to prevent fatty acid accumulation. Nonetheless, because of this requirement, a substantial amount of the glucose used in adipocytes is used to generate glycerol backbones. In the absence of glucose, gluconeogenic precursors such as lactate and pyruvate can be converted to glycerol in adipocytes, a process known as glyceroneogenesis<sup>11</sup>.

<sup>11</sup> This is equivalent to gluconeogenesis, up to the DHAP step, where reaction 7 takes precedence over the Aldolase reaction.

THE ENERGY COSTS OF TRIGLYCERIDE SYNTHESIS, based on these pathways is substantial. Three acyl chains must be activated at a cost of 2 ATP equivalents each for 6 ATP in total. This is tissue independent. In the liver, one more ATP to activate glycerol so a total 7 ATP are required to form one triglyceride. In adipose tissue the cost is more because you use 2 x ATP in the preparation phase of glycolysis and another NADH to form Glycerol-3-phosphate in reaction 7. This means the cost in adipose tissue is 10.5 ATP, so it is not only more energy demanding, but also consumes some of the glucose that would be used to generate those ATP molecules.

### Regulation of Triglyceride Esterification Enzymes

Both in the liver and in adipose triglyceride synthesis will increase in response to insulin. The mechanisms of this include both short-term and long term regulation. Recall first, that in adipocytes glucose uptake is increased by insulin via stimulation of GLUT4 translocation. Insulin can acutely activate GPAT<sup>12</sup> and Lipin<sup>13</sup>. Together the increased glucose and fatty acid flux, combined with more activity of these triglyceride synthetizing enzymes will result in efficient triglyceride storage in adipose tissue after a meal. Simultaneous to these effects, as we will discuss in the lipid transport lecture, insulin also suppresses triglyceride breakdown, a process known as *lipolysis*. For more insights into how insulin regulates triglyceride synthesis, see the recent review by Coleman and Mashek [2011].


CHRONIC REGULATION OF TRIGLYCERIDE SYNTHESIS IS TRANSCRIPTIONAL and is regulated by the two transcription factors SREBP1c<sup>14</sup> and PPAR $\gamma$ <sup>15</sup>. Both of these nuclear hormone receptors increase the number of the key triglyceride synthesis enzymes, including GPAT, Lipin and AGPAT<sup>16</sup>. The regulation of SREBP1c is quite complicated but involves insulin- and mTORC1-dependent signals (reviewed in Bakan and Laplante [2012]). In this way both insulin and nutritional status can promote the efficiency of triglyceride storage.

### De Novo Fatty Acid Synthesis

Triglycerides can use fatty acids derived from the diet, or that are generated endogenously. Certain fatty acids (the  $\omega$ 3 and  $\omega$ 6 derived fatty acids) are entirely dependent on nutritional inputs, but others are generated endogenously. This can vary substantially, with individuals on a high carbohydrate diet generating many of their fatty acids *de novo*, with those on a low carbohydrate diet relying almost entirely on dietary intake. All tissues can perform this function<sup>17</sup>, but the major sites are liver and adipose tissue.

### Fatty Acid Synthesis from Glucose and Ketogenic Amino Acids

Fatty acid biosynthesis occurs in the endoplasmic reticulum, which presents the first problem in terms of substrates. The initial input, Acetyl-CoA is generated from its precursors<sup>18</sup> in the mitochondria, and there are no Acetyl-CoA transporters. Therefore Acetyl-CoA must first be converted to Citrate via Citrate Synthase<sup>19</sup>:



<sup>12</sup> The enzyme that catalyzes reaction 2.

<sup>13</sup> The enzyme that catalyzes reaction 4, this is mediated by activation of mTORC1 [Harris et al., 2007]

<sup>14</sup> Sterol response element binding protein 1c, which has a similar isoform SREBP2, that plays a key role in cholesterol synthesis, more on this in the next section.

<sup>15</sup> This stands for Peroxisome proliferator-activated receptor gamma, a nuclear hormone receptor which promotes both triglyceride synthesis and new adipocyte formation. It is the target of the anti-diabetic drugs of the thiazolidinedione family.


<sup>16</sup> Which catalyzes reaction 2.

<sup>17</sup> As it may be important for phospholipid synthesis

<sup>18</sup> Hypothetically from pyruvate via Pyruvate Dehydrogenase, from ketogenic amino acids or as the product of  $\beta$ -oxidation, though the latter is unlikely as the cell will not typically break down fatty acids and then immediately resynthesize them.

<sup>19</sup> This is the same Citrate Synthase that is the first step of the TCA cycle.


Citrate transporters do exist in the mitochondria, so citrate is removed and then reconverted to Acetyl-CoA via an enzyme called ATP-Citrate Lyase via the following reaction:




Once the Acetyl-CoA is in the cytoplasm<sup>20</sup>, the next and rate-limiting step is catalyzed by an enzyme called *Acetyl-CoA Carboxylase* or ACC. This enzyme catalyzes the following reaction:



Malonyl-CoA<sup>21</sup> and Acetyl-CoA are both the substrates for Fatty Acid Synthase, a multifunctional enzyme that catalyzes the next several reactions. Acetyl-CoA serves as both a primer *As in an initial substrate* and a source of carbon units<sup>22</sup>. The first round generates a four carbon fatty acid condensing Acetyl-CoA and Malonyl-CoA and using two NADPH<sup>23</sup> molecules. After that, each round of the reaction consumes two NADPH and another Malonyl-CoA, resulting in the sequential addition of carbons two at a time. This ends when the acyl chain is 16 carbons long, releasing Palmitate, a C16:0 fatty acid. In sum the overall reaction for a single palmitate is:



THE NADPH REQUIREMENTS OF FATTY ACID SYNTHESIS ARE HIGH. Each palmitate requires 14 NADPH molecules along with a substantial amount of ATP. The NADPH comes from two sources the pentose phosphate shunt<sup>24</sup>, and the activity of Malic Enzyme. Recall from above, when a Citrate molecule is exported, the other product of ATP-Citrate Lyase, shown in reaction 9, is oxaloacetate. While this is used as a TCA intermediate in the mitochondria, in the cytoplasm OAA can be converted into pyruvate via Malic Dehydrogenase and Malic Enzyme. This reactions are:



In sum this reaction uses a cytosolic NADH and the released oxaloacetate to generate NADPH and two pyruvate molecules, which can then be re-oxidized in the mitochondria. This means that for each

<sup>20</sup> As we will discuss later, the Oxaloacetate from ATP-Citrate Lyase activity in the cytoplasm is also important for generating reducing agents. This is described in reaction 12 below.

<sup>21</sup> When levels of this lipid are high (reflecting high ACL and ACC activity and active lipogenesis, it inhibits the transport of fatty acids back into the mitochondria by inhibiting Carnitine Palmitoyltransferase I. More on this in the lipid oxidation unit.

<sup>22</sup> Through MalonylCoA generated by ACC

<sup>23</sup> Not NADH, remember this from the pentose phosphate shunt?

<sup>24</sup> Wherein one glucose molecule yields one NADPH molecule.

Citrate released and Acetyl-CoA generated by ATP-Citrate Lyase, one NADPH is regenerated (again, at a cost of an NADH). This helps to maintain the NADPH pool. Therefore we can suspect that the 8 Acetyl-CoA's needed in reaction 11 will come with 8 NADPH molecules, so on average we need 6 more from the pentose phosphate shunt. This means we need the equivalent of 6 molecules of glucose to go through the pentose phosphate pathway, and still need to generate 7 ATP, 8 NADH (equivalent to 20 ATP) and 8 Acetyl-CoA molecules (This requires 4 Glucoses, but generates 12 NADH and 4 ATP during partial oxidation) to power the formation of a single palmitic acid. This means a net requirement of 16 glucose molecules to make a single palmitic acid, at a net gain of only 11 ATP equivalents of energy<sup>25</sup>. Recall that if those same glucose molecules were to undergo complete oxidation it would yield 512 ATP<sup>26</sup>. This is a huge diversion of resources for making a single fatty acid.

<sup>25</sup> The exact math here is unimportant, since this is simplified scenario, but the point is that you have to use up a lot of glucose without gaining a lot of energy to make a single fatty acid

<sup>26</sup> 16 Glucose x 32 ATP/glucose.

### *Desaturation of Fatty Acids*

While palmitate is the initial fatty acid made by mammals, this fatty acid (C16:0) can be further modified by both elongases and desaturases. Elongases can extend dietary or *de novo* fatty acids by increments of two by adding another Malonyl-CoA moiety and using two more NADPH molecules. This results in the synthesis of very long chain fatty acids. There are several elongases in the human genome, but mutations in *ELOVL4* have been linked to macular dystrophy, highlighting the importance of fatty acid elongation in the conversion of ALA to DHA [Zhang et al., 2001]. Adipocytes and liver cells express high levels of *ELOVL6*, which elongates fatty acids to a maximum of 18 carbons. This is one reason<sup>27</sup> why the primary *de novo* synthesized fatty acids end up as C16:0, C16:1 $\Delta^9$ , C18:0, and C18:1 $\Delta^9$  in these tissues.

<sup>27</sup> The other is the activity of SCD1, the  $\Delta^9$  desaturase.

HUMANS HAVE FOUR DESATURASES that work on the  $\Delta_4$ ,  $\Delta_5$ ,  $\Delta_6$  and  $\Delta_9$  positions of a fatty acid. The enzymes that catalyze these reactions are FADS1 and FADS2, which we discussed in terms of PUFA metabolism and the Stearoyl-CoA Desaturase<sup>28</sup>. The desaturation is a key part of the assembly of triglycerides and phospholipids, as a desaturated fatty acid is preferentially attached to the sn2 position. Both desaturases and elongases can alter the structure of both dietary and endogenously produced fatty acids.

<sup>28</sup> Abbreviated SCD.

### *Regulation of Fatty Acid Synthesis*

Two steps of fatty acid biosynthesis are under relatively acute control. ATP-Citrate Lyase is phosphorylated and activated by insulin-

dependent signaling through Akt [Berwick et al., 2002], whereas Acetyl-CoA Carboxylase is dephosphorylated and activated, also in an Akt-dependent manner [Witters and Kemp, 1992]. The inactivation of ACC is due to phosphorylation by both PKA<sup>29</sup> or AMPK<sup>30</sup>, so the role of insulin is to reverse that inhibition. The precise process by which insulin and Akt mediate this dephosphorylation is not clear at this stage.

CITRATE IS A FEED-FORWARD REGULATOR OF ACC. When citrate is exported to the cytoplasm, it serves as an activator of ACC and results in the production of more Malonyl-CoA [Vagelos et al., 1963]. Cytoplasmic citrate is also a potent negative regulator of phosphofructokinase 1<sup>31</sup>. This means that when there is excessive Acetyl-CoA production, and if ATP-Citrate Lyase is active, citrate production will *block* glycolysis while promoting lipogenesis. In this way, glucose can be saved<sup>32</sup> when there is sufficient substrates to store energy as lipid. This is *not* the case for fructolysis, which does not require PFK1. An implication of this is that even when there is sufficient Acetyl-CoA to make lipids, dietary fructose will continue to be processed into more Acetyl-CoA. This positive feedback loop, occurring mainly in the liver will result in more lipogenesis. This is proposed to be the biochemical mechanism by which fructose consumption is associated with the development of NAFLD<sup>33</sup> [Lim et al., 2010].

AT A CHRONIC LEVEL, FATTY ACID BIOSYNTHESIS IS REGULATED BY TRANSCRIPTIONAL CONTROL OF SEVERAL ENZYMES. SREBP1c, discussed earlier, promotes the synthesis of Fatty Acid Synthase, ACC, ATP-Citrate Lyase, SCD1 and several of the elongases [Horton et al., 2002, Moon et al., 2012]. Another transcriptional regulator is the more recently described ChREBP<sup>34</sup>. This transcription factor is activated by excessive carbohydrates, and especially in the liver, results in the activation of many of the same lipid synthetic proteins<sup>35</sup>. ChREBP is thought to play a key role in fructose's strong lipogenic effects in the liver [Kim et al., 2016].

### *Lipodistrophy Results from Impaired Triglyceride Storage*

We may generally consider fatty acid formation and storage as negative, as increased adiposity is causal of obesity, which now affects over a third of Americans [Flegal et al., 2016]. However fat synthesis and storage is also essential for normal physiological function. Disorders or impairments of either adipocyte generation, or lipid storage result in a disease termed *lipodistrophy*. In this condition, fatty acids are unable to be stored effectively as triglycerides in adipose depots

<sup>29</sup> In response to glucagon or adrenaline signaling

<sup>30</sup> The AMP-Activated Protein Kinase, In response to energy needs.

<sup>31</sup> Remember this from the glycolysis unit?

<sup>32</sup> For example, stored as glycogen.

<sup>33</sup> Non-alcoholic fatty liver disease.

<sup>34</sup> Carbohydrate Response Element Binding Protein


<sup>35</sup> More information about ChREBP can be found in Baraille et al. [2015].



and therefore are ectopically deposited in tissues such as liver and muscle, promoting their impairment and inducing insulin resistance. A recent genetic association study showed that among normal weight seeming individuals with insulin resistance and hyperlipidemia, variants in lipogenic and adipogenic genes were associated with this phenotype [Lotta et al., 2016]. This may also be part of the reason why some ethnic groups, such as those of Chinese descent, have increased diabetes and liver disease risk, at adiposity levels that pose less risk for those of European descent [Chiu et al., 2011].

### *Cholesterol Synthesis*

All cells are able to produce cholesterol, and in all cases the rate limiting enzyme is *HMG-CoA Reductase*, abbreviated HMGCR<sup>36</sup>. Prior to this step, there is reversible reactions interconverting Acetyl-CoA and Acetoacetyl-CoA and then an irreversible reaction<sup>37</sup> catalysed by HMG-CoA Synthase:




This produces the intermediate HMG-CoA. At this stage the pathway branches between cholesterol synthesis and <sup>38</sup>. HMG-CoA has two potential fates:

*If HMG-CoA Reductase is Active:* The HMG-CoA continues along to irreversibly become mevalonate and then cholesterol

*If HMG-CoA Lyase is Present and HMGCR is Inactive:* HMG-CoA is cleaved to form Acetoacetate, which in turn can be converted into  $\beta$ -Hydroxybutyrate and Acetone the three major ketone bodies. This is thought to occur primarily in the liver.

The reaction catalyzed by HMGCR is:



Because the steps other than HMGCR and HMG-CoA Lyase are generally reversible there are some key consequences. First, a build up of Acetyl-CoA will result in increased flux through this system. This will occur when fatty acid oxidation<sup>39</sup> occurs but energy demands are insufficient to pull Acetyl-CoA through the TCA cycle. Second, this means that in most tissues that are not ketogenic, excessive Acetyl-CoA will result in increased cholesterol synthesis. As we will discuss below there is some negative feedback to this system but

<sup>36</sup> The HMG-CoA here stands for 3-hydroxy-3-methylglutaryl-CoA

<sup>37</sup> In liver, this reaction is reversible in muscle tissues and other tissues that can utilize ketone bodies

<sup>38</sup> ketogenesis

<sup>39</sup> This generates a lot of Acetyl-CoA, but this is also true if there is excessive PDH activity or ketogenic amino acid catabolism.

endogenous cholesterol synthesis is the primary mechanism of hypercholesterolemia. Third, in tissues that are ketogenic, ketone bodies can be produced if there is insufficient oxaloacetate and/or insufficient TCA cycle activity. Efficient ketone body production, export and usage can alleviate this overflow of Acetyl-CoA, but its worth considering that the tissues that the ketone bodies traffic to also need to have efficient energy demands and TCA cycle activity to use those for energy. Otherwise ketone bodies are converted back to HMG-CoA and can become cholesterol there.

THE ACTIVITY OF HMGR IS THEREFORE THE MOST IMPORTANT REGULATORY STEP IN CHOLESTEROL SYNTHESIS. This reaction is regulated by allosteric, post-translational and transcriptional mechanisms. There is negative feedback inhibition, via a mevalonate-derived product which reduces the activity of HMGR, but to date the endogenous inhibitor has not been found. Instead, much like Acetyl-CoA Carboxylase, HMGR is phosphorylated and inhibited by the AMPK-Activated Protein Kinase (AMPK). This means that when energy levels are low, Acetyl-CoA is not converted to cholesterol but instead is converted to ATP<sup>40</sup>.

#### SENSING AND REGULATION OF STEROL BIOSYNTHESIS BY SREBP2.

At the transcriptional level HMGR is controlled by the transcription factor SREBP2. This transcription factor is normally present in the endoplasmic reticulum where it is inactive. Once it is activated, SREBP2 would drive the transcriptional upregulation of HMGR, HMGCS and the LDLR<sup>41</sup>. SREBP2 is maintained in the ER, in an inactive form by high cholesterol levels. This mechanism means that when cholesterol levels in the tissue are high, cholesterol synthesis is reduced but when the cholesterol levels in the tissue are low these genes are activated.

HMG-CoA REDUCTASE IS THE TARGET OF STATINS. Inhibition of HMGR by drugs will reduce endogenous cholesterol reduction, an approach that has proven far more effective than dietary restriction in the reduction of blood cholesterol levels. Currently one in five Americans above the age of 40 take a statin, which is a HMG-CoA Reductase inhibitor. These drugs are quite effective, reducing the risk of cardiovascular events by approximately 20% [Cholesterol Treatment Trialists' Collaboration, 2010]. There are some serious side effects of statins however, including a small but significant risk of diabetes and an increased risk in muscle breakdown, potentially due to reductions in CoEnzyme Q<sup>42</sup>.

<sup>40</sup> Of course, the reverse is also true; that when ATP levels are high, HMGR levels are also high.

<sup>41</sup> The Low-Density Lipoprotein Receptor, which is used to scavenge cholesterol in the form of LDL back into the liver. This will be covered in the lipid transport lecture.

<sup>42</sup> This was discussed way back in the TCA cycle lecture, where we discussed how CoEnzyme Q, an electron carrier in the electron transport chain is generated from cholesterol.

### *The Relationship Between Dietary Fat and Cholesterol Synthesis*

There is a very weak, if any association between dietary cholesterol and blood cholesterol<sup>43</sup> in most people. There is however, a strong negative association between MUFA and PUFA intake and both LDL/HDL ratio and cardiovascular risk [Hu et al., 1998, Zong et al., 2016]. Consistent with this, a large randomized controlled trial with a high intake of PUFA and MUFA containing foods reduced cardiovascular events by about 30% [Estruch et al., 2013]. The exact mechanisms by which saturated fats promote cholesterol biogenesis, while MUFA and PUFA do not are still under investigation.

<sup>43</sup> In particular cholesterol present in LDL, but reductions in HDL cholesterol

### *References*

Inan Bakan and Mathieu Laplante. Connecting mTORC1 signaling to SREBP-1 activation. *Current opinion in lipidology*, pages 1–9, mar 2012. ISSN 1473-6535. DOI: 10.1097/MOL.obo13e328352dd03. URL <http://www.ncbi.nlm.nih.gov/pubmed/22449814>.

Floriane Baraille, Julien Planchais, Renaud Dentin, Sandra Guilmeau, and Catherine Postic. Integration of ChREBP-Mediated Glucose Sensing into Whole Body Metabolism. *Physiology*, 30(6): 428–437, 2015. ISSN 1548-9213. DOI: 10.1152/physiol.00016.2015. URL <http://physiologyonline.physiology.org/lookup/doi/10.1152/physiol.00016.2015>.

Daniel C Berwick, Ingeborg Hers, Kate J Heesom, S Kelly Moule, and Jeremy M Tavare. The Identification of ATP-citrate Lyase as a Protein Kinase B (Akt) Substrate in Primary Adipocytes. *Journal of Biological Chemistry*, 277(37):33895–33900, 2002. URL <http://www.jbc.org/cgi/content/full/277/37/33895>.

H Brockerhoff. Stereospecific analysis of triglycerides. *Lipids*, 6(12): 942–56, dec 1971. ISSN 0024-4201. URL <http://www.ncbi.nlm.nih.gov/pubmed/4950467>.

Maria Chiu, Peter C. Austin, Douglas G. Manuel, Baiju R. Shah, and Jack V. Tu. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. *Diabetes Care*, 34(8):1741–1748, 2011. ISSN 01495992. DOI: 10.2337/dc10-2300.

Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. *The Lancet*, 376(9753):1670–1681, 2010. ISSN 01406736. DOI: 10.1016/S0140-6736(10)61350-5. URL [http://dx.doi.org/10.1016/S0140-6736\(10\)61350-5](http://dx.doi.org/10.1016/S0140-6736(10)61350-5).

Rosalind A. Coleman and Douglas G. Mashek. Mammalian triacylglycerol metabolism: Synthesis, lipolysis, and signaling. *Chemical Reviews*, 111(10):6359–6386, 2011. ISSN 00092665. DOI: 10.1021/cr100404w.

Ramón Estruch, Emilio Ros, Jordi Salas-Salvadó, Maria-Isabel Covas, Dolores Corella, Fernando Arós, Enrique Gómez-Gracia, Valentina Ruiz-Gutiérrez, Miquel Fiol, José Lapetra, Rosa Maria Lamuela-Raventos, Lluís Serra-Majem, Xavier Pintó, Josep Basora, Miguel Angel Muñoz, José V. Sorlí, José Alfredo Martínez, and Miguel Angel Martínez-González. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. *New England Journal of Medicine*, 368(14):1279–1290, 2013. ISSN 0028-4793. DOI: 10.1056/NEJMoa1200303. URL <http://www.nejm.org/doi/10.1056/NEJMoa1200303>.

Katherine M. Flegal, Deanna Kruszon-Moran, Margaret D. Carroll, Cheryl D. Fryar, and Cynthia L. Ogden. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA*, 315(21):2284, 2016. ISSN 0098-7484. DOI: 10.1001/jama.2016.6458. URL <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.6458>.

Thurl E. Harris, Todd A Huffman, An Chi, Jeffrey Shabanowitz, Donald F Hunt, Anil Kumar, and John C Lawrence. Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. *The Journal of biological chemistry*, 282(1):277–86, jan 2007. ISSN 0021-9258. DOI: 10.1074/jbc.M609537200. URL <http://www.ncbi.nlm.nih.gov/pubmed/17105729>.

Jay D. Horton, Joseph L. Goldstein, and Michael S. Brown. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *Journal of Clinical Investigation*, 109(9):1125–1131, may 2002. ISSN 0021-9738. DOI: 10.1172/JCI200215593. URL <http://www.jci.org/articles/view/15593>.

Frank B. Hu, Meir J Stampfer, JoAnn E Manson, Eric Rimm, Graham A Colditz, Bernard A Rosner, Charles H Hennekens, Walter C. Willett, and Meir J Stampfer. Dietary fat intake and the risk of coronary heart disease in women. *The New England journal of medicine*, 338(13):918–9, 1998. ISSN 0028-4793. DOI: 10.1056/NEJM199711203372102. URL <http://www.ncbi.nlm.nih.gov/pubmed/15781956>.

Claudia Kent. Eukaryotic Phospholipid Biosynthesis. *Annual Review of Biochemistry*, 64(1):315–343, 1995. ISSN 0066-4154.

DOI: 10.1146/annurev.bi.64.070195.001531. URL <http://www.annualreviews.org/doi/10.1146/annurev.bi.64.070195.001531>.

Mi-Sung Kim, Sarah A Krawczyk, Ludivine Doridot, Alan J Fowler, Jennifer X Wang, Sunia A Trauger, Hye-lim Noh, Hee Joon Kang, John K Meissen, Matthew Blatnik, Jason K Kim, Michelle Lai, and Mark A Herman. ChREBP regulates fructose-induced glucose production independently of insulin signaling. *Journal of Clinical Investigation*, 126(11):4372–4386, sep 2016. ISSN 0021-9738. DOI: 10.1172/JCI81993. URL <https://www.jci.org/articles/view/81993>.

Jung Sub Lim, Michele Mietus-Snyder, Annie Valente, Jean-Marc Schwarz, and Robert H. Lustig. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. *Nature Reviews Gastroenterology & Hepatology*, 7(5):251–264, may 2010. ISSN 1759-5045. DOI: 10.1038/nrgastro.2010.41. URL <http://dx.doi.org/10.1038/nrgastro.2010.41>.

Luca A Lotta, Pawan Gulati, Felix R Day, Felicity Payne, Halit Ongen, Martijn van de Bunt, Kyle J Gaulton, John D Eicher, Stephen J Sharp, Jian'an Luan, Emanuella De Lucia Rolfe, Isabel D Stewart, Eleanor Wheeler, Sara M Willems, Claire Adams, Hanieh Yaghootkar, EPIC-InterAct Consortium, Cambridge FPLD1 Consortium, Nita G Forouhi, Kay-Tee Khaw, Andrew D Johnson, Robert K Semple, Timothy Frayling, John R. B. Perry, Emmanouil Dermitzakis, Mark I McCarthy, Inês Barroso, Nicholas J Wareham, David B Savage, Claudia Langenberg, Stephen P O'Rahilly, and Robert A. Scott. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. *Nature genetics*, 49 (November), 2016. ISSN 1546-1718. DOI: 10.1038/ng.3714. URL <http://www.ncbi.nlm.nih.gov/pubmed/27841877>.

Young-Ah Ah Moon, Guosheng Liang, Xuefen Xie, Maria Frank-Kamenetsky, Kevin Fitzgerald, Victor Koteliansky, Michael S. Brown, Joseph L. Goldstein, and Jay D. Horton. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. *Cell Metabolism*, 15(2):240–246, feb 2012. ISSN 15504131. DOI: 10.1016/j.cmet.2011.12.017. URL <http://dx.doi.org/10.1016/j.cmet.2011.12.017>.

John L Tymoczko, Jeremy M Berg, and Lubert Stryer. *Biochemistry: A Short Course*. W.H. Freeman and Co, New York, NY, 3rd edition, 2015.

P R Vagelos, A W Alberts, and D B Martin. Studies on the mechanism of activation of acetyl coenzyme A carboxylase by citrate. *The Journal of biological chemistry*, 238(2):533–40, feb 1963. ISSN 0021-9258. URL <http://www.ncbi.nlm.nih.gov/pubmed/13995702>.

L. A. Witters and B. E. Kemp. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5'-AMP-activated protein kinase. *The Journal of biological chemistry*, 267(5):2864–7, feb 1992. ISSN 0021-9258. DOI: 10.1146/ANNUREV.NUTR.19.1.463. URL <http://www.ncbi.nlm.nih.gov/pubmed/1346611>.

Kang Zhang, Marina Kniazeva, Min Han, Wen Li, Zhengya Yu, Zhenglin Yang, Yang Li, L Michael, Rando Allikmets, Donald J Zack, Laura E Kakuk, Pamela S Lagali, Paul W Wong, M Ian, Paul A Sieving, David J Figueroa, Christopher P Austin, Robert J Gould, Konstantin Petrukhin, and Stargardt-like Stgd. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. *American Journal of Ophthalmology*, 131(5):689, 2001. ISSN 00029394. DOI: 10.1016/S0002-9394(01)00952-7. URL <http://linkinghub.elsevier.com/retrieve/pii/S0002939401009527>.

Geng Zong, Yanping Li, Anne J Wanders, Marjan Alsema, Peter L Zock, Walter C. Willett, Frank B. Hu, and Qi Sun. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. *Bmj*, 355, 2016. ISSN 1756-1833. DOI: 10.1136/bmj.i5796.